Susan Chi, MD
Dana-Farber Cancer Institute · Dana Farber/ Boston Children's Cancer and Blood Disorders Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Susan Chi, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:48 UTC. Open this list on ClinicalTrials.gov
- Early Ph1NCT06333899 · Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK FusionNationwide Children's Hospital · recruiting · High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma · study chair
- Ph1/Ph2NCT05407441 · Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsSusan Chi, MD · active not recruiting · Atypical Teratoid Rhabdoid Tumor, INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors, SMARCA4-deficient Primary CNS Malignant Tumors · principal investigator
- Early Ph1NCT04655404 · A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK FusionNationwide Children's Hospital · recruiting · High Grade Glioma, Diffuse Intrinsic Pontine Glioma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in atypical teratoid rhabdoid tumour (at/rt).